```
     FILE 'REGISTRY' ENTERED AT 12:43:42 ON 02 MAY 2009
                  EXP CS-682/CN
                  EXP CS682/CN
                  EXP CS 682/CN
L1                1 S E3
                  EXP 1-(2-C-CYANO/CN
                  EXP 1-(2-CYANO/CN
                  EXP 1-(2-CYANO-2-DEOXY/CN

     FILE 'HCAPLUS' ENTERED AT 12:45:49 ON 02 MAY 2009
L2               28 S L1
L3            32326 S CDC OR (CYCLIN DEPENDENT KINASE) OR CDC2 OR CDC4

     FILE 'STNGUIDE' ENTERED AT 12:46:22 ON 02 MAY 2009

     FILE 'HCAPLUS' ENTERED AT 12:47:36 ON 02 MAY 2009
L4               28 S L1 AND L2
L5            29617 S CDK OR (CYCLIN DEPENDENT KINASE) OR CDK2 OR CDK4
L6                4 S L2 AND L5

     FILE 'REGISTRY' ENTERED AT 12:58:20 ON 02 MAY 2009
                  EXP CNDAC/CN
L7                1 S E3

     FILE 'HCAPLUS' ENTERED AT 12:58:40 ON 02 MAY 2009
L8               51 S L7
L9                1 S L5 AND L8

     FILE 'REGISTRY' ENTERED AT 13:00:41 ON 02 MAY 2009
                  EXP ROSOVITINE/CN
                  EXP ROSCOVITINE/CN
L10               1 S E3
L11               0 S PURVALANOL/CN
                  EXP PURVALANOL/CN
L12               2 S E4-E5
                  EXP OLOMOUCINE/CN
L13               1 S E3

     FILE 'HCAPLUS' ENTERED AT 13:01:55 ON 02 MAY 2009
L14             708 S L10 OR L12 OR L13
L15               3 S (L2 OR L8) AND L14
```

```
=>  file regisry
'REGISRY' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'HOME'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 12:43:42 ON 02 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 APR 2009  HIGHEST RN 1141557-64-3
DICTIONARY FILE UPDATES:  30 APR 2009  HIGHEST RN 1141557-64-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> exp CS-682/cn
E1            1     CS-144M/CN
E2            1     CS-516/CN
E3            0 --> CS-682/CN
E4            1     CS-7002/CN
E5            1     CS-728/CN
E6            1     CS-80L/CN
E7            1     CS-834 DIHYDRATE/CN
E8            1     CS-834 MONOHYDRATE/CN
E9            1     CS-ACT CEREBROSIDE SULFATE ACTIVATOR GLYCOPROTEIN (PIG KIDNE
                    Y)/CN
E10           1     CS-AU 44JO/CN
E11           1     CS-AV 44IO/CN
E12           1     CS-BK 100Y/CN

=> exp CS682/cn
E1            1     CS61+/CN
E2            1     CS6790/CN
E3            0 --> CS682/CN
E4            1     CS6NA18SN46/CN
E5            1     CS7/CN
E6            1     CS7+/CN
E7            1     CS71+/CN
```

```
E8            1     CS74A/CN
E9            1     CS8/CN
E10           1     CS8+/CN
E11           1     CS81+/CN
E12           1     CS8GA8SN38/CN

=> exp CS 682/cn
E1            1     CS 670/CN
E2            1     CS 674A/CN
E3            1 --> CS 682/CN
E4            1     CS 684/CN
E5            1     CS 6DE/CN
E6            1     CS 6E227/CN
E7            1     CS 6E227S/CN
E8            1     CS 6PA/CN
E9            1     CS 6PA422CB/CN
E10           1     CS 6PA473/CN
E11           1     CS 6PE231/CN
E12           1     CS 6PE401/CN

=> s e3
L1            1 "CS 682"/CN

=> d l1
<------User Break------>

=> d l1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   151823-14-2  REGISTRY
ED   Entered STN:  17 Dec 1993
CN   Hexadecanamide, N-[1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-1,2-
     dihydro-2-oxo-4-pyrimidinyl]-  (CA INDEX NAME)
OTHER NAMES:
CN   CS 682
CN   CYC 682
CN   Sapacitabine
FS   STEREOSEARCH
MF   C26 H42 N4 O5
SR   CA
LC   STN Files:   ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB,
       CIN, EMBASE, IMSDRUGNEWS, IMSRESEARCH, IPA, PHAR, PROMT, PROUSDDR,
       RTECS*, SYNTHLINE, TOXCENTER, USAN, USPATFULL
         (*File contains numerically searchable property data)

Absolute stereochemistry.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
```

```
              27 REFERENCES IN FILE CA (1907 TO DATE)
               3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
              28 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> exp 1-(2-C-cyano/cn
E1            1     1-(2-BUTYRYLOXYETHOXY)ETHYL METHACRYLATE/CN
E2            1     1-(2-C-ALLYL-B-D-RIBOFURANOSYL)THYMINE/CN
E3            0 --> 1-(2-C-CYANO/CN
E4            1     1-(2-CARBAMOYL-1-METHYLETHYL)-1-METHYLPYRROLIDINIUM IODIDE/C
                    N
E5            1     1-(2-CARBAMOYL-1-METHYLETHYL)PYRIDINIUM BROMIDE/CN
E6            1     1-(2-CARBAMOYL-1-METHYLETHYL)PYRIDINIUM CHLORIDE/CN
E7            1     1-(2-CARBAMOYL-1-METHYLETHYL)PYRIDINIUM IODIDE/CN
E8            1     1-(2-CARBAMOYL-4-(6-FLUORO-7-(METHYLAMINO)-4-OXO-2H-BENZO(E)
                    (1,3)OXAZIN-3(4H)-YL)PHENYL)-3-((5-CHLOROTHIOPHEN-2-YL)SULFO
                    NYL)UREA/CN
E9            1     1-(2-CARBAMOYLETHYL)-1-METHYLPIPERIDINIUM BROMIDE/CN
E10           1     1-(2-CARBAMOYLETHYL)-1-PYRIDINIUM METHANESULFONATE/CN
E11           1     1-(2-CARBAMOYLETHYL)-2-(P-DIETHYLAMINOPHENYL)BENZ(CD)INDOLIU
                    M CHLORIDE/CN
E12           1     1-(2-CARBAMOYLETHYL)-2-METHYLPYRIDINIUM PICRATE/CN

=> exp 1-(2-cyano/cn
E1            1     1-(2-CIS-(4-AZIDO-3-((TERT-BUTYLDIMETHYLSILYL)OXY)PIPERIDIN-
                    1-YL)ETHYL)-2-OXO-1,2-DIHYDROQUINOLINE-7-CARBONITRILE/CN
E2            1     1-(2-CIS-(4-AZIDO-3-HYDROXYPIPERIDIN-1-YL)ETHYL)-2-OXO-1,2-D
                    IHYDROQUINOLINE-7-CARBONITRILE/CN
E3            0 --> 1-(2-CYANO/CN
E4            1     1-(2-CYANO-1-METHYLETHYL)-2-ETHYLIMIDAZOLE/CN
E5            1     1-(2-CYANO-1-METHYLETHYL)-2-ETHYLIMIDAZOLE MONOPICRATE/CN
E6            1     1-(2-CYANO-1-METHYLETHYL)-2-ISOPROPYLIMIDAZOLE/CN
E7            1     1-(2-CYANO-1-METHYLETHYL)-2-ISOPROPYLIMIDAZOLE MONOPICRATE/C
                    N
E8            1     1-(2-CYANO-3'-METHYLBIPHENYL-4-YL)-1H-PYRAZOLE-4-CARBOXYLIC
                    ACID/CN
E9            1     1-(2-CYANO-3'-METHYLBIPHENYL-4-YL)-1H-PYRAZOLE-4-CARBOXYLIC
                    ACID ETHYL ESTER/CN
E10           1     1-(2-CYANO-3,4-DIMETHOXYPHENYL)-3-BUTYLUREA/CN
E11           1     1-(2-CYANO-3,4-DIMETHOXYPHENYL)-3-METHYLUREA/CN
E12           1     1-(2-CYANO-3-METHYLPHENOXY)-2,3-EPOXYPROPANE/CN

=> exp 1-(2-cyano-2-deoxy/cn
E1            1     1-(2-CYANO-1-METHYLETHYL)-2-ISOPROPYLIMIDAZOLE/CN
E2            1     1-(2-CYANO-1-METHYLETHYL)-2-ISOPROPYLIMIDAZOLE MONOPICRATE/C
                    N
E3            0 --> 1-(2-CYANO-2-DEOXY/CN
E4            1     1-(2-CYANO-3'-METHYLBIPHENYL-4-YL)-1H-PYRAZOLE-4-CARBOXYLIC
                    ACID/CN
E5            1     1-(2-CYANO-3'-METHYLBIPHENYL-4-YL)-1H-PYRAZOLE-4-CARBOXYLIC
                    ACID ETHYL ESTER/CN
E6            1     1-(2-CYANO-3,4-DIMETHOXYPHENYL)-3-BUTYLUREA/CN
E7            1     1-(2-CYANO-3,4-DIMETHOXYPHENYL)-3-METHYLUREA/CN
E8            1     1-(2-CYANO-3-METHYLPHENOXY)-2,3-EPOXYPROPANE/CN
E9            1     1-(2-CYANO-3-METHYLPHENOXY)-2-HYDROXY-3-ISOPROPYLAMINOPROPAN
                    E HYDROCHLORIDE/CN
E10           1     1-(2-CYANO-3-METHYLPHENOXY)-2-HYDROXY-3-TERT-BUTYLAMINOPROPA
                    NE-HYDROCHLORIDE/CN
E11           1     1-(2-CYANO-3-PYRAZINYL)-4-(3-(6-METHYL-2-PYRIDYL)-2-PROPYNYL
                    IDENE)PIPERIDINE/CN
```

```
E12          1     1-(2-CYANO-3-TRIFLUOROMETHYLPHENYL)PIPERAZINE/CN

=> file hcaplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      12.70      12.92

FILE 'HCAPLUS' ENTERED AT 12:45:49 ON 02 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 2 May 2009  VOL 150 ISS 19
FILE LAST UPDATED: 1 May 2009  (20090501/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l2
L2 NOT FOUND
The L-number entered has not been defined in this session, or it
has been deleted.  To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l1
L2           28 L1

=> s CDC or (cyclin dependent kinase) or CDC2 or CDC4
          3564 CDC
         40000 CYCLIN
       1214183 DEPENDENT
        348522 KINASE
         25058 CYCLIN DEPENDENT KINASE
                 (CYCLIN(W)DEPENDENT(W)KINASE)
          4823 CDC2
           237 CDC4
L3        32326 CDC OR (CYCLIN DEPENDENT KINASE) OR CDC2 OR CDC4

=> file stnguide
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       2.85      15.77
```

```
FILE 'STNGUIDE' ENTERED AT 12:46:22 ON 02 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 24, 2009 (20090424/UP).

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.14      15.91

FILE 'HCAPLUS' ENTERED AT 12:47:36 ON 02 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 May 2009  VOL 150 ISS 19
FILE LAST UPDATED: 1 May 2009  (20090501/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l1 and l2
           28 L1
L4         28 L1 AND L2

=> s CDk or (cyclin dependent kinase) or CDk2 or CDk4
         6363 CDK
        40000 CYCLIN
      1214183 DEPENDENT
       348522 KINASE
        25058 CYCLIN DEPENDENT KINASE
                (CYCLIN(W)DEPENDENT(W)KINASE)
         5724 CDK2
         4188 CDK4
L5      29617 CDK OR (CYCLIN DEPENDENT KINASE) OR CDK2 OR CDK4

=> s l2 and l5
L6          4 L2 AND L5

=> d l6 1-4 ti abs bib
```

L6 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Compositions of placentally-derived stem cells for the treatment of cancer
AB Disclosed are prepns. of placentally-derived stem cells and compns. useful for the treatment of cancer. Said stem cells and compns. function through inducing a "guided differentiation" program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents. Within the context of this disclosure, methods for inducing host responses to cancer are also described.
AN 2007:86292 HCAPLUS <<LOGINID::20090502>>
DN 146:169222
TI Compositions of placentally-derived stem cells for the treatment of cancer
IN Ichim, Thomas E.
PA Medistem Laboratories, Inc., USA
SO PCT Int. Appl., 41pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007011693	A2	20070125	WO 2006-US27305	20060712
	WO 2007011693	A3	20070510		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	US 20070041954	A1	20070222	US 2006-486635	20060713
PRAI	US 2005-699579P	P	20050714		

L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Combination of a CDK inhibitor and CS-682 or a metabolite thereof
AB A first aspect of the invention relates to a combination comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or sep. use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or sep. administering a CDK inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.
AN 2005:523291 HCAPLUS <<LOGINID::20090502>>
DN 143:48129
TI Combination of a CDK inhibitor and CS-682 or a metabolite thereof
IN Green, Simon; Sleigh, Roger Neil
PA Cyclacel Limited, UK
SO PCT Int. Appl., 27 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005053699	A1	20050616	WO 2004-GB5081	20041203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1711185	A1	20061018	EP 2004-805910	20041203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007513132	T	20070524	JP 2006-542014	20041203
US 20070270442	A1	20071122	US 2007-581585	20070420
PRAI GB 2003-28180	A	20031204		
WO 2004-GB5081	W	20041203		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
AB The invention discloses the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
AN 2004:1036851 HCAPLUS <<LOGINID::20090502>>
DN 142:696
TI Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
IN Kandimalla, Ekambar R.; Agrawal, Sudhir; Wang, Daqin
PA Hybridon, Inc., USA
SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004103301	A2	20041202	WO 2004-US15313	20040514
WO 2004103301	A3	20051103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004241093	A1	20041202	AU 2004-241093	20040514

```
     CA 2526212           A1    20041202    CA 2004-2526212        20040514
     US 20050009773       A1    20050113    US 2004-846167         20040514
     EP 1628531           A2    20060301    EP 2004-752345         20040514
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
     JP 2006528697        T     20061221    JP 2006-533117         20040514
     MX 2005012421        A     20060222    MX 2005-12421          20051116
     US 20080206265       A1    20080828    US 2008-20694          20080128
PRAI US 2003-471247P      P     20030516
     US 2004-846167       A1    20040514
     WO 2004-US15313      W     20040514
OS   MARPAT 142:696
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6   ANSWER 4 OF 4  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Methods for enhancing antibody-induced cell lysis and treating cancer
AB   The invention relates to methods and products for treating cancer.  In
     particular the invention relates to combinations of nucleic acids and
     antibodies for the treatment and prevention of cancer.  The invention also
     relates to diagnostic methods for screening cancer cells.
AN   2001:935435  HCAPLUS <<LOGINID::20090502>>
DN   136:84677
TI   Methods for enhancing antibody-induced cell lysis and treating cancer
IN   Weiner, George; Hartmann, Gunther
PA   University of Iowa Research Foundation, USA
SO   PCT Int. Appl., 312 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
PI   WO 2001097843         A2    20011227    WO 2001-US20154        20010622
     WO 2001097843         A3    20030123
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
             VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2410371           A1    20011227    CA 2001-2410371        20010622
     AU 2001070134        A     20020102    AU 2001-70134          20010622
     US 20030026801       A1    20030206    US 2001-888326         20010622
     EP 1296714           A2    20030402    EP 2001-948684         20010622
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2003535907        T     20031202    JP 2002-503327         20010622
     AU 2001270134        B2    20060615    AU 2001-270134         20010622
     AU 2006216542        A1    20061012    AU 2006-216542         20060915
PRAI US 2000-213346P      P     20000622
     AU 2001-270134       A3    20010622
     WO 2001-US20154      W     20010622
RE.CNT  2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his
```

```
     (FILE 'HOME' ENTERED AT 12:43:26 ON 02 MAY 2009)

     FILE 'REGISTRY' ENTERED AT 12:43:42 ON 02 MAY 2009
                EXP CS-682/CN
                EXP CS682/CN
                EXP CS 682/CN
L1             1 S E3
                EXP 1-(2-C-CYANO/CN
                EXP 1-(2-CYANO/CN
                EXP 1-(2-CYANO-2-DEOXY/CN

     FILE 'HCAPLUS' ENTERED AT 12:45:49 ON 02 MAY 2009
L2            28 S L1
L3         32326 S CDC OR (CYCLIN DEPENDENT KINASE) OR CDC2 OR CDC4

     FILE 'STNGUIDE' ENTERED AT 12:46:22 ON 02 MAY 2009

     FILE 'HCAPLUS' ENTERED AT 12:47:36 ON 02 MAY 2009
L4            28 S L1 AND L2
L5         29617 S CDK OR (CYCLIN DEPENDENT KINASE) OR CDK2 OR CDK4
L6             4 S L2 AND L5

=> log hold
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  14.85      30.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -3.28      -3.28

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:48:11 ON 02 MAY 2009

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 12:58:06 ON 02 MAY 2009
FILE 'HCAPLUS' ENTERED AT 12:58:06 ON 02 MAY 2009
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  14.85      30.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -3.28      -3.28

=> file registry
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
```

```
FULL ESTIMATED COST                                    14.85      30.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -3.28      -3.28

FILE 'REGISTRY' ENTERED AT 12:58:20 ON 02 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 APR 2009  HIGHEST RN 1141557-64-3
DICTIONARY FILE UPDATES:  30 APR 2009  HIGHEST RN 1141557-64-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> exp CNDAC/cn
E1            1     CNC68/CN
E2            1     CNCC/CN
E3            1 --> CNDAC/CN
E4            1     CNDP DIPEPTIDASE 2 (METALLOPEPTIDASE M20 FAMILY) (HUMAN CLON
                    E MGC:4413 IMAGE:2957870)/CN
E5            1     CNDP DIPEPTIDASE 2 (METALLOPEPTIDASE M20 FAMILY) (HUMAN CLON
                    E MGC:928 IMAGE:3051369)/CN
E6            1     CNDP DIPEPTIDASE 2 (METALLOPEPTIDASE M20 FAMILY) (MOUSE STRA
                    IN MIX FVB/N, C57BL/6J CLONE MGC:7671 IMAGE:3496319)/CN
E7            1     CNDP DIPEPTIDASE 2 (METALLOPEPTIDASE M20 FAMILY) (XENOPUS TR
                    OPICALIS CLONE MGC:75655 IMAGE:5379710 GENE CNDP2-PROV)/CN
E8            1     CNDP2-PROV PROTEIN (XENOPUS LAEVIS CLONE MGC:82085 IMAGE:701
                    1654 GENE CNDP2-PROV)/CN
E9            1     CNDR-29/CN
E10           1     CNDR-3/CN
E11           1     CNE 195LB/CN
E12           1     CNE 195XL2/CN

=> s e3
L7            1 CNDAC/CN

=> d l7

L7   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   135598-68-4  REGISTRY
ED   Entered STN:  16 Aug 1991
CN   2(1H)-Pyrimidinone, 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-
     (CA INDEX NAME)
OTHER NAMES:
```

CN CNDAC
FS STEREOSEARCH
MF C10 H12 N4 O4
CI COM
SR CA
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, IMSRESEARCH,
      PROUSDDR, TOXCENTER, USPATFULL
        (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

51 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
51 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.88	38.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.28

FILE 'HCAPLUS' ENTERED AT 12:58:40 ON 02 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 May 2009 VOL 150 ISS 19
FILE LAST UPDATED: 1 May 2009 (20090501/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l7
L8 51 L7

=> s l5 and l8
L9 1 L5 AND L8

=> d l9 ti abs bib

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine
AB 2'-C-Cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC), the prodrug (sapacitabine) of which is in clin. trials, has the novel mechanism of action of causing single-strand breaks after incorporating into DNA. Cells respond to this unique lesion by activating the G2 checkpoint, affected by the Chk1-Cdc25C-cyclin-dependent kinase 1/cyclin B pathway. This study aims at defining DNA damage checkpoint sensors that activate this response to CNDAC, particularly focusing on the major phosphatidylinositol 3-kinase-like protein kinase family proteins. First, fibroblasts, deficient in ataxia-telangiectasia mutated (ATM), transfected with empty vector or repleted with ATM, were arrested in G2 by CNDAC to similar extents, suggesting ATM is not required to activate the G2 checkpoint. Second, chromatin assocns. of RPA70 and RPA32, subunits of the ssDNA-binding protein, and the ataxia-telangiectasia and Rad3-related (ATR) substrate Rad17 and its phosphorylated form were increased on CNDAC exposure, suggesting activation of ATR kinase. The G2 checkpoint was abrogated due to depletion of ATR by small interfering RNA, and impaired in ATR-Seckel cells, indicating participation of ATR in this G2 checkpoint pathway. Third, the G2 checkpoint was more stringent in glioma cells with wild-type DNA-dependent protein kinase catalytic subunit (DNA-PKcs) than those with mutant DNA-PKcs, as shown by mitotic index counting. CNDAC-induced G2 arrest was abrogated by specific DNA-PKcs inhibitors or small interfering RNA knockdown in ML-1 and/or HeLa cells. Finally, two phosphatidylinositol 3-kinase-like protein kinase inhibitors, caffeine and wortmannin, abolished the CNDAC-induced G2 checkpoint in a spectrum of cell lines. Together, our data showed that ATR and DNA-PK cooperate in CNDAC-induced activation of the G2 checkpoint pathway. [Mol Cancer Ther 2008;7(1):133-42].
AN 2008:64824 HCAPLUS <<LOGINID::20090502>>
DN 148:322141
TI Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine
AU Liu, Xiaojun; Matsuda, Akira; Plunkett, William
CS Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
SO Molecular Cancer Therapeutics (2008), 7(1), 133-142
CODEN: MCTOCF; ISSN: 1535-7163
PB American Association for Cancer Research
DT Journal

```
LA   English
RE.CNT  50    THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 12:43:26 ON 02 MAY 2009)

     FILE 'REGISTRY' ENTERED AT 12:43:42 ON 02 MAY 2009
                EXP CS-682/CN
                EXP CS682/CN
                EXP CS 682/CN
L1            1 S E3
                EXP 1-(2-C-CYANO/CN
                EXP 1-(2-CYANO/CN
                EXP 1-(2-CYANO-2-DEOXY/CN

     FILE 'HCAPLUS' ENTERED AT 12:45:49 ON 02 MAY 2009
L2           28 S L1
L3        32326 S CDC OR (CYCLIN DEPENDENT KINASE) OR CDC2 OR CDC4

     FILE 'STNGUIDE' ENTERED AT 12:46:22 ON 02 MAY 2009

     FILE 'HCAPLUS' ENTERED AT 12:47:36 ON 02 MAY 2009
L4           28 S L1 AND L2
L5        29617 S CDK OR (CYCLIN DEPENDENT KINASE) OR CDK2 OR CDK4
L6            4 S L2 AND L5

     FILE 'REGISTRY' ENTERED AT 12:58:20 ON 02 MAY 2009
                EXP CNDAC/CN
L7            1 S E3

     FILE 'HCAPLUS' ENTERED AT 12:58:40 ON 02 MAY 2009
L8           51 S L7
L9            1 S L5 AND L8

=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       5.85      44.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.82      -4.10

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:59:29 ON 02 MAY 2009

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 13:00:33 ON 02 MAY 2009
```

```
FILE 'HCAPLUS' ENTERED AT 13:00:33 ON 02 MAY 2009
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)f

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       5.85      44.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.82      -4.10

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       5.85      44.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.82      -4.10

FILE 'REGISTRY' ENTERED AT 13:00:41 ON 02 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 APR 2009  HIGHEST RN 1141557-64-3
DICTIONARY FILE UPDATES:  30 APR 2009  HIGHEST RN 1141557-64-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> exp rosovitine/cn
E1            1     ROSOPHENINE 4B/CN
E2            1     ROSOPHENINE G/CN
E3            0 --> ROSOVITINE/CN
E4            1     ROSOXACIN/CN
E5            1     ROSOXIDE/CN
E6            1     ROSPIGLIOSIDE/CN
E7            1     ROSPIGLIOSIDE AGLYCON/CN
E8            1     ROSPIN/CN
E9            1     ROSPINE/CN
E10           1     ROSPOL MP32/CN
E11           1     ROSS 160/CN
E12           1     ROSS WAX 160/CN

=> exp roscovitine/cn
E1            1     ROSCOPENIN/CN
```

```
E2            1     ROSCOVITIN/CN
E3            1 --> ROSCOVITINE/CN
E4            1     ROSCOVITINE CARBOXYLIC ACID/CN
E5            1     ROSE ACETONE/CN
E6            1     ROSE ALLOY/CN
E7            1     ROSE B 1333/CN
E8            1     ROSE BD/CN
E9            1     ROSE BENGAL/CN
E10           1     ROSE BENGAL (131I) SODIUM/CN
E11           1     ROSE BENGAL 3-IODOPROPYL ESTER MONOSODIUM SALT/CN
E12           1     ROSE BENGAL 4-BROMOBUTYL ESTER MONOSODIUM SALT/CN

=> s e3
L10           1 ROSCOVITINE/CN

=> s purvalanol/cn
L11           0 PURVALANOL/CN

=> exp purvalanol/cn
E1            1     PURUSEA SQE 10C/CN
E2            1     PURUVATE DEHYDROGENASE COMPLEX, E2 COMPONENT, DIHYDROLIPOAMI
                    DE ACETYLTRANSFERASE (LACTOBACILLUS SAKEI SAKEI STRAIN 23K G
                    ENE PDHC)/CN
E3            0 --> PURVALANOL/CN
E4            1     PURVALANOL A/CN
E5            1     PURVALANOL B/CN
E6            1     PUS/CN
E7            1     PUS (POLYMER)/CN
E8            1     PUS 1/CN
E9            1     PUS 2/CN
E10           1     PUS-A/CN
E11           1     PUS-B/CN
E12           1     PUS-C/CN

=> s e4-e5
              1 "PURVALANOL A"/CN
              1 "PURVALANOL B"/CN
L12           2 ("PURVALANOL A"/CN OR "PURVALANOL B"/CN)

=> exp olomoucine/cn
E1            1     OLOGEN/CN
E2            1     OLOMOUCIN/CN
E3            1 --> OLOMOUCINE/CN
E4            1     OLOMOUCINE II/CN
E5            1     OLON/CN
E6            1     OLOPATADINE/CN
E7            1     OLOPATADINE HYDROCHLORIDE/CN
E8            1     OLOTHORB/CN
E9            1     OLPADRONATE/CN
E10           1     OLPADRONIC ACID/CN
E11           1     OLPFW/CN
E12           1     OLPI/CN

=> s e3
L13           1 OLOMOUCINE/CN

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                27.71      72.20
```

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -4.10

FILE 'HCAPLUS' ENTERED AT 13:01:55 ON 02 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 May 2009 VOL 150 ISS 19
FILE LAST UPDATED: 1 May 2009 (20090501/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l10 or l12 or l13
           543 L10
           128 L12
           266 L13
L14        708 L10 OR L12 OR L13

=> s (l2 or l8) and l14
L15          3 (L2 OR L8) AND L14

=> d l15 1-3 ti abs bib

L15  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Compositions and methods using Stat3 pathway inhibitors or cancer stem
     cell inhibitors for combination cancer treatment
AB   The present invention relates to the composition and methods of use of Stat3
     pathway inhibitors or cancer stem cell inhibitors in combination treatment
     of cancer.
AN   2009:332545  HCAPLUS <<LOGINID::20090502>>
DN   150:345478
TI   Compositions and methods using Stat3 pathway inhibitors or cancer stem
     cell inhibitors for combination cancer treatment
IN   Li, Chiang Jia; Mikule, Keith; Li, Youzhi
PA   Boston Biomedical, Inc., USA
SO   PCT Int. Appl., 81pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 3
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009036101	A1	20090319	WO 2008-US75906	20080910
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2007-971144P	P	20070910		
	US 2007-13372P	P	20071213		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells

AB This study assessed the antiproliferative activity of sapacitabine (CYC682, CS-682) in a panel of 10 human cancer cell lines with varying degrees of resistance or sensitivity to the commonly used nucleoside analogs ara-C and gemcitabine. Growth inhibition studies using sapacitabine and CNDAC were performed in the panel of cell lines and compared with both nucleoside analogs and other anticancer compds. including oxaliplatin, doxorubicin, docetaxel and seliciclib. Sapacitabine displayed antiproliferative activity across a range of concns. in a variety of cell lines, including those shown to be resistant to several anticancer drugs. Sapacitabine is biotransformed by plasma, gut and liver amidases into CNDAC and causes cell cycle arrest predominantly in the G2/M phase. No clear correlation was observed between sensitivity to sapacitabine and the expression of critical factors involved in resistance to nucleoside analogs such as deoxycytidine kinase (dCK), human equilibrative nucleoside transporter 1, cytosolic 5'-nucleotidase and DNA polymerase-α. However, sapacitabine showed cytotoxic activity against dCK-deficient L1210 cells indicating that in some cells, a dCK-independent mechanism of action may be involved. In addition, sapacitabine showed a synergistic effect when combined with gemcitabine and sequence-specific synergy with doxorubicin and oxaliplatin. Sapacitabine is therefore a good candidate for further evaluation in combination with currently used anticancer agents in tumor types with unmet needs.

AN 2007:959718 HCAPLUS <<LOGINID::20090502>>
DN 148:92336

TI Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells

AU Serova, M.; Galmarini, C. M.; Ghoul, A.; Benhadji, K.; Green, S. R.; Chiao, J.; Faivre, S.; Cvitkovic, E.; Le Tourneau, C.; Calvo, F.; Raymond, E.
CS RayLab - Department of Medical Oncology, Hopital Beaujon, Clichy, 92110, Fr.

SO British Journal of Cancer (2007), 97(5), 628-636
CODEN: BJCAAI; ISSN: 0007-0920
PB Nature Publishing Group
DT Journal
LA English

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Combination of a CDK inhibitor and CS-682 or a metabolite thereof
AB A first aspect of the invention relates to a combination comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or sep. use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or sep. administering a CDK inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.
AN 2005:523291 HCAPLUS <<LOGINID::20090502>>
DN 143:48129
TI Combination of a CDK inhibitor and CS-682 or a metabolite thereof
IN Green, Simon; Sleigh, Roger Neil
PA Cyclacel Limited, UK
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005053699	A1	20050616	WO 2004-GB5081	20041203
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1711185	A1	20061018	EP 2004-805910	20041203
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	JP 2007513132	T	20070524	JP 2006-542014	20041203
	US 20070270442	A1	20071122	US 2007-581585	20070420
PRAI	GB 2003-28180	A	20031204		
	WO 2004-GB5081	W	20041203		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT